Latest From Christina Vasiliou
Pipeline-In-A-Pill: Still A Winning Strategy?
-
Analysis
“Pipeline-in-a-pill” has increasingly entered the biopharma executive’s vernacular, denoting an attractive asset that has considerable sales potential owing to the number of discrete patient populations it can target. While the phrase or concept may be in vogue, in reality it is one of the many guises or iterations of lifecycle management.
Pfizer's Xeljanz Is First JAK Positive In PsA But Challenges Ahead
Pfizer’s oral JAK inhibitor Xeljanz is set to lead the JAK inhibitors to market in psoriatic arthritis following positive Phase III data particularly in joint inflammation, but skin findings were disappointing.
Email Author
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.